US Bancorp
NGNE icon

US Bancorp’s Neurogene NGNE Stock Holding History

US Bancorp’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$605 Sell
30
-133
-82% -$2.58K ﹤0.01% 3987
2025
Q4 		$3.36K Buy
163
+152
+1,382% +$3.78K ﹤0.01% 3645
2025
Q3 		$191 Hold
11
– – ﹤0.01% 3948
2025
Q2 		$164 Hold
11
– – ﹤0.01% 4088
2025
Q1 		$129 Sell
11
-32
-74% -$556 ﹤0.01% 4131
2024
Q4 		$983 Sell
43
-69
-62% -$2.57K ﹤0.01% 3958
2024
Q3 		$4.7K Sell
112
-13
-10% -$504 ﹤0.01% 3588
2024
Q2 		$4.55K Buy
+125
New +$4.41K ﹤0.01% 3548
2024
Q1 		– Sell
-3,467
Closed -$67.2K – 4056
2023
Q4 		$67.2K Hold
3,467
– – ﹤0.01% 2518
2023
Q3 		$54.8K Buy
3,467
+1,250
+56% +$18.5K ﹤0.01% 2400
2023
Q2 		$36.8K Hold
2,217
– – ﹤0.01% 2664
2023
Q1 		$31K Buy
2,217
+1,167
+111% +$13.7K ﹤0.01% 2755
2022
Q4 		$10.7K Hold
1,050
– – ﹤0.01% 3278
2022
Q3 		$13K Hold
1,050
– – ﹤0.01% 3271
2022
Q2 		$22K Buy
1,050
+500
+91% +$12.2K ﹤0.01% 2999
2022
Q1 		$21K Buy
+550
New +$32.1K ﹤0.01% 3046
2021
Q4 		– Sell
-8
Closed -$1K – 4188
2021
Q3 		$1K Buy
+8
New +$1.23K ﹤0.01% 3993

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

US Bancorp's NGNE Position: Q1 2026 in Review

US Bancorp reduced its Neurogene (NGNE) stake by 82% in Q1 2026, selling an estimated $2.58K and leaving 30 shares worth $605. The position accounts for ﹤0.01% of the portfolio, ranked #3987.

US Bancorp first reported a position in NGNE in Q3 2021 and has held it in 17 quarters since. The position peaked at $67.2K in Q4 2023. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • US Bancorp held 30 shares of Neurogene worth $605 as of Q1 2026.
  • US Bancorp sold 133 Neurogene shares in Q1 2026, an estimated $2.58K.
  • Neurogene made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3987 holding.
  • US Bancorp first reported a position in Neurogene in Q3 2021 and has held it in 17 quarters since.
  • US Bancorp's Neurogene position peaked at $67.2K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.